Why people use BPC-157 for tendinitis
You have tendon pain that won't quit; will BPC-157 help? The honest answer: the animal evidence is genuinely strong, but the human trials are still thin. Animal studies showed accelerated Achilles tendon healing on systemic BPC-157 (Gwyer et al., 2010).
This page covers what's known, what's not, and what the editorial take is for normal humans considering BPC-157 for tendinitis.
What the evidence says
Evidence tier: Strong animal evidence. Decades of consistent animal evidence; human RCTs are sparse but the mechanism is well-established.
- Animal studies showed accelerated Achilles tendon healing on systemic BPC-157 (Gwyer et al., 2010).
- Mechanism: appears to drive new blood-vessel growth in damaged tissue.
- Most-discussed peptide for tendon recovery on the internet, despite no human RCTs.
Protocol notes
Subcutaneous injection near (not into) the affected tendon, 250-500mcg/day, 4-6 weeks. Always with sports-medicine doctor sign-off.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full BPC-157 directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch